Certara buys CRO Synchrogenix as regulatory writing sees more outsourcing

By Zachary Brennan

- Last updated on GMT

Related tags: Pharmacology, Clinical trial, Contract research organization

Certara buys Synchrogenix as regulatory writing sees more outsourcing
Consultancy and drug developer Certara has acquired specialty contract research organization (CRO) Synchrogenix Information Strategies, which offers regulatory writing and related services to biopharma and medical device companies worldwide. 

Financial details of the acquisition were not disclosed.The acquisition comes as the market for outsourced regulatory writing is seeing more growth, Certara spokeswoman Lisa Osborne told Outsourcing-pharma.com

The regulatory writing market is on the upswing as more biopharma and medical device companies are outsourcing these services​,” Osborne said. “There’s a shortage of employees with the requisite background as it’s a highly specialized niche market.”

The acquisition will combine Delaware-based Synchrogenix, which is the largest independent regulatory-writing CRO in the world, with Certara, which offers scientific informatics and analytics, including molecular modeling, population-based simulations, pharmacokinetic analyses and clinical trial simulations.

Certara has more than 225 employees located at offices in the US, UK, Canada, and Japan.

Synchrogenix has more than 50 permanent regulatory writers and editors on staff, located in seven offices in North America, Europe, and Asia. The company provides pre-clinical, clinical, CMC and drug safety writing, and global regulatory submission services.

The acquisition occurred now as Certara was looking to expand its small regulatory writing team in Montreal more globally, Osborne said. The two companies also have overlapping clients, but they’re dealing with different individuals in the groups. The objective is to synchronize those discussions into a more continuous process for the client, she said.

 “We were attracted to Synchrogenix by the quality of its work, its outstanding reputation and the global network of regulatory experts that it has developed. By combining the most sophisticated regulatory professional organization with the world’s leading computational drug development capabilities, we believe that Certara can continue to enable our clients to improve the pace of efficacious drug development for the benefit of patients around the world​,” Donald Deieso, Chairman of Certara, added.

Related topics: Markets & Regulations, Regulatory affairs

Related news

Related products

show more

Empowering Clinical Trial Sponsors with Analytics

Empowering Clinical Trial Sponsors with Analytics

PerkinElmer | 14-Jul-2021 | Technical / White Paper

Is your Clinical Data Review creating problems or solving them? Take Control of Your Data. PerkinElmer Informatics Clinical Solutions, powered by Tibco...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Covance Touchless Drug and Device Vigilance Vision

Covance Touchless Drug and Device Vigilance Vision

Covance Patient Safety | 01-Sep-2020 | Data Sheet

Automation tools enable organizations to identify patterns in structured and unstructured data and facilitate automation of the entire product vigilance...

Related suppliers

Follow us


View more